Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA® Trial
figureposted on 2020-06-15, 09:46 authored by Hirotaka Watada, Hiroyuki Sakamaki, Daisuke Yabe, Fumiko Yamamoto, Tatsunori Murata, Keigo Hanada, Tetsuaki Hirase, Tomoo Okamura
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.